What We Do
Research at Deep Blue Retina
When conducting in-house clinical research, the Deep Blue Retina team analyzes findings and works to develop novel therapeutics for improved patient care. In a healthcare landscape dominated by medical practices owned by either large corporate financial groups or large hospital systems, DBR brought its attention back to the two human components of the medical experience: the patient and the doctor.
The Deep Blue Retina facility and laboratory is located just outside Memphis in Southaven, MS.
The Future of Medicine
One of the stated missions of Deep Blue Retina is to be deeply involved in the future of medicine. The best way to achieve it is through collaboration with the medical technology and the biotechnology industries, where novel therapeutics are being developed. We are then able to offer our patients therapies that may help with their blinding conditions years before they are commercially available.
By participating in clinical research, patients can benefit from a new treatment that could help make vision clearer or provide better care for eye diseases.
Highest Medical Standards
Our team works with industry in clinical research protocols from early development, through phase 1, 2 and 3 of clinical trials. This not only puts our practice in the midst of forward-thinking therapeutic development. This guarantees that our whole team, from our doctors to our technicians, are validated and certified by outside third parties to the highest levels of clinical excellence. The diagnostic and therapeutic technologies used are also validated and certified to be at the top of medical standards.
Our Current Clinical Studies
Our primary concern for all research protocols is the safety of our patients. Once you are interested in participating in a clinical trial, we will give you all of the information that you and your family need to learn about the trial.
Your very first visit will be the Screening visit. The purpose of this visit is to assess your eligibility for the study. The Informed Consent process will be conducted to ensure your comprehension about the study and your voluntary participation. In addition, there are tests that will need to be done that include but are not limited to vital signs, blood work, ophthalmic examination, and imaging. These tests will be the elements to determine your eligibility for the study. Throughout the course of the study, we will always make sure to prioritize your safety and well-being.
- 2026
- Clinical Trials
- Diabetic Retinopathy
- Exudative Age-related Macular Degeneration
- Geographic Atrophy
The SIENNA Study
Sponsor: REGENERON Trial Summary This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD). Geographic atrophy is a medical term that refers to later-stage cases of AMD which is an eye condition affecting central vision (what one…
The LUGANO Study
Sponsor: EyePoint Pharmaceuticals Trial Summary This study is researching an experimental (study) drug called EYP-1901 for people with wet Age-Related Macular Degeneration (wAMD), a condition that can cause loss of central vision due to abnormal blood vessel growth and leakage in the retina. The study is comparing EYP-1901 with aflibercept, an approved treatment for wAMD.…
The Izervay Study
Sponsor: Astellas Trial Summary This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person’s central vision to worsen. Geographic atrophy is an advanced form of AMD where…
The HONU Study
Sponsor: Genentech Trial Summary This is a multicenter prospective study in participants with intermediate age-related macular degeneration (iAMD). One primary objective of this study is to assess iAMD disease progression, by the timeline and rates of conversion for high-risk iAMD at baseline to more advanced atrophic AMD stages. The other primary objective of this observational…
The EVOLVE Study
Sponsor: Astellas Trial Summary This study is focused on people with Stargardt disease (STGD) and STGD-like macular dystrophies, inherited retinal conditions that affect the macula and can lead to progressive loss of central vision. STGD is most commonly caused by changes in the ABCA4 gene, while STGD-like conditions are linked to several other genetic mutations.…
The ELARA Study
Sponsor: REGENERON Trial Summary This study is researching aflibercept high dose (HD), referred to as “study drug”, with an experimental dosing regimen. The study is focused on participants with nAMD and DME that have been previously treated with anti-vascular endothelial growth factor (anti-VEGF) medications. The aim of the study is to see how safe and…
The CRIMSON Study
Sponsor: Boehringer-Ingelheim Trial Summary This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study. The purpose of this study is to find out whether a medicine called BI 764524 helps people with diabetic retinopathy. The study also aims to find a…
The ASP7317 Study
Sponsor: Astellas Trial Summary Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina – the light-sensitive part at the back of the eye. There are 2 types of AMD – wet AMD and…
The ARTEMIS Study
Sponsor: Adverum Trial Summary This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection of Ixo-vec compared to an active comparator. The primary endpoint of this study is the mean change…
The 4FRONT-1 Study
Sponsor: 4D Molecular Therapeutics Trial Summary A Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration. 4D-150 is currently being evaluated in the 4FRONT-1 and 4FRONT-2 Phase 3 clinical trials and the ongoing Phase 1/2 PRISM clinical trial in adults with wet AMD. 4D-150 is also being evaluated in Part 1…
Our Previous Clinical Studies
Over the years, we have proudly participated in numerous clinical research studies focused on advancing treatments for retinal and ophthalmic diseases. These studies have contributed to the development of innovative therapies and have helped improve care for patients facing a variety of vision-related conditions.
Every clinical trial conducted at our site follows strict regulatory and ethical guidelines to ensure participant safety, privacy, and well-being. Our experienced research team works closely with study sponsors, physicians, and participants to maintain the highest standards of care throughout each study.
We are grateful to the patients who have chosen to participate in our previous clinical trials. Their involvement has played an important role in helping researchers gain valuable insights into new treatments and technologies. Through these efforts, we continue to support advancements in eye care while remaining committed to providing a safe, professional, and patient-centered research experience.
- Past Trials
- Clinical Trials
- Diabetic Macular Edema
- Diabetic Retinopathy
- Geographic Atrophy
- Intermediate Age-Related Macular Degeneration
- Neovascular Age-Related Macular Degeneration
The Photon Study
A randomized, double-masked, active-controlled phase 2/3 study of the efficacy and safety of high-dose aflibercept in patients with Diabetic Macular Edema. This study focuses on the efficacy, effectiveness, and safety of high-dose aflibercept in patients with diabetic macular edema. Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor that is administered intravitreally.
The OTT166-201 Study
A phase 2 randomized, double-masked, vehicle controlled, multicenter study to evaluate the safety and efficacy of OTT166 ophthalmic solution in the treatment of diabetic retinopathy. This study evaluates the safety and effectiveness of OTT166, an eye drop intended to treat patients with diabetic retinopathy. Patients who had moderately severe to severe non-proliferative or moderately proliferative…
The Luna Study
A multi-center, randomized, double-masked phase 2 study to assess safety and efficacy of ADVM-022 (AAV.7m8-aflibercept) in anti-VEGF treatment-experienced patients with neovascular (wet) age-related macular degeneration. This study evaluates the efficacy and safety of ADVM-022. This is a gene therapy that delivers aflibercept, a known anti-VEGF (vascular endothelial growth factor) agent. The study enrolled patients with…
The Isis 696844-CS5 Study
A phase 2, randomized, placebo-controlled, double-masked study to assess safety and efficacy of multiple doses of Ionis- FB0LRX, an antisense inhibitor of complement factor B, in patients with Geographic Atrophy secondary to Age-Related Macular Degeneration. The study’s primary purpose was to assess both the safety and efficacy of multiple doses of Ionis-FB0LRX, an antisense inhibitor specifically…
The GE43220 Study
A multicenter, prospective, observational study of the progression of intermediate age-related macular degeneration. This study is dedicated to exploring the progression of intermediate age-related macular degeneration. This observational study will help and potentially guide future researchers to the treatment or prevention of age-related macular degeneration. This study is 36 months long, allowing researchers to have…
The Canberra Study
A randomized, double-masked, 48-week, parallel-group, placebo-controlled, proof-of-concept study to investigate the efficacy and safety of RG7774 in patients with diabetes mellitus type 1 or type 2 with treatment-naïve diabetic retinopathy. This study investigates the efficacy and safety of RG7774, an oral medication, for patients with moderately severe to severe non-proliferative diabetic retinopathy. The 48-week duration…
The Bardenas Study
A phase 2, multicenter, randomized, double masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7200220 in combination with ranibizumab administered intravitreally in patients with Diabetic Macular Edema. The study aims to evaluate whether the combination of RO7200220 and ranibizumab can provide improved outcomes in terms of both efficacy and…
The ASPIRE Study
A prospective, multicenter, randomized, double-masked active-controlled study to assess the efficacy and safety of repeat intravitreal injections of foselutoclax (UBX1325) in patients with diabetic macular edema This study will assess the safety and efficacy of foselutoclax (UBX1325) following repeated intravitreal injections in patients with diabetic macular edema. The medication is intended to remove certain types…
The ALXN2040-GA-201 Study
A phase 2, double-masked, placebo-controlled, does range finding study of Danicopan (ALXN2040) in patients with geographic atrophy secondary to Age-Related Macular Degeneration. This study intends to identify the most effective and well-tolerated dosage of Danicopan, an oral medication. Geographic atrophy, a severe form of Age-Related Macular Degeneration characterized by the progressive loss of retinal cells,…
The Alluvium Study
A phase 2, multicenter, randomized, double masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7200220 administered intravitreally in patients with Diabetic Macular Edema. The study’s primary focus is on evaluating the efficacy of RO7200220, comparing its performance against an active comparator, ranibizumab, a standard treatment. Comprehensive assessments of safety…